Best practice on transport qualification: good distribution practice

Transport validations “were like building a new Eiffel Tower every time,” said Kim Bang Salling, Transport Validation Expert at Novo Nordisk. “The documentation effort and tests were enormous and time-consuming. What we want is to move to something more like the Arc de Triomphe – simple, dependable and robust.”

Shipping lane validation or qualification of thermal protection systems – temperature controlled cool boxes if you like – would seem to be a simple enough task. It is not. Each pharmaceutical company and regulatory body use different standards and processes leading to inconsistency across the industry.  This is compounded by the fact that temperature-controlled vehicles, equipment and packaging all present a variety of complex challenges from a regulatory compliance point of view.

 

Vendors also don’t have a standard for the specific tests that customers require. This often leads to a huge amount of resources being dedicated to qualification testing, where work is unnecessarily repeated and existing data is not leveraged.

To solve these issues, BioPhorum Drug Substance Storage and Transport workstream has produced a best practice paper – Best Practice on Transport Qualification: Good Distribution Practice – which proposes standardizing shipping lane validation.

The team estimates that establishing a standard approach could deliver an annual saving of between $0.5m and $1m per shipping solution, as well as a 50% reduction in resource requirements. Also, product submission timelines could be cut by as much as 6-12 months and the risk of a regulatory finding would also diminish.

A standard approach

Vendors are required to complete operational qualification testing to prove that a thermal protection system will stay at the correct temperature, whatever the varying extremes on the outside.

However, each company that buys a solution wants the vendor to carry out the testing in a different way. This leads to costly, repeat testing, which the vendor cannot always complete in the way that the pharmaceutical company wants. Consequently, the customer often has to repeat some of that testing to satisfy its own requirements.

By standardizing qualification testing, vendors would have a standard test and the end-user could utilize the results without the need for any repeat testing. As well as advocating one standard approach, the best practice paper provides guidance on interpreting the various tests that different regulatory bodies require.

How was it achieved?

While the project was launched in September 2016, it really began in March 2017 with a face-to-face meeting in North Carolina involving eight biopharmaceutical manufacturers. In 2018, vendors such as DHL and CCT – the companies that make the thermal protection systems and move the materials around the globe – came on board, providing invaluable feedback on the draft best practice paper.

Another key part of the collaboration was the team’s decision to present at the Temperature Controlled Logistics conferences in 2018 and 2019. This provided the opportunity to speak with vendors and other biopharmaceutical manufacturers across the entire industry – engaging them in the project and inviting further feedback.

As a result, rather than take a big leap and introduce a brand-new best practice with immediate effect – which would be extremely difficult for all parties to comply with – the workstream has proposed an incremental change approach. Rather than make a ‘true north’ best practice, we are going to shift the bell curve.

Next steps

Although the best practice paper has been published, the work does not stop there – industry needs to implement it. A face-to-face meeting planned for September will review the implementation status – establishing what is working and what is not, refining the approach and proposing updates to the best practice guide, as appropriate.

“There isn’t really an end [to the project],” said BioPhorum’s Tim Corbidge. “It’s an ongoing process to move it forward and get the industry to use it.”

While there may not be an overnight one-size-fits-all solution, the bell curve is definitely tolling for haphazard shipping lane validation.

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
The BioPhorum and USP collaborative journey to new standards

BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration.

Read More
Perfecting balanced scorecards for CDMOs

Established in March 2017, the Development Group’s Development Outsourcing effort aims to share and build guidance that will help companies make the best decisions and[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Why leaders should go to where work is performed to learn about success, failure and risk
Read More
Decision tree to improve single-use change notification classification

The BioPhorum/BPSA change notification team have made the paper “A guide to the classification of changes to single-use biomanufacturing systems” available here.

Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Companies poised to follow ARMM recommendations

The Advanced and Rapid Microbial Methods (ARMM) team set out a clear case for modernizing Environmental Monitoring (EM) in grade A settings: in summary bio-fluorescent[...]

Read More
How to achieve the ‘Goldilocks’ amount of environmental monitoring

Regulators require a risk-based approach to environmental monitoring (EM)… but they give no clear definition of what “risk-based” actually means. The aim of the Environmental[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
BioPhorum and Rx-360 pilot a joint audit model for single-use systems

BioPhorum and Rx-360 have agreed a pilot to validate the use of the Joint Audit Model in the single-use systems supply chain.

Read More
Removing the roadblocks to continuous biomanufacturing

Continuous downstream processing is increasingly seen as a feasible approach for manufacturing biologics. The industry recognises that it offers advantages over batch-based processing by:

Read More
Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

Read More
How do you bring technology roadmapping to life?

You use it to make change happen and that is exactly what the Phorum’s leaders did after the first edition of the Biomanufacturing Technology Roadmaps[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More